Open access peer-reviewed chapter

Dual L/N-Type Ca2+ Channel Blocker: Cilnidipine as a New Type of Antihypertensive Drug

By Akira Takahara

Submitted: June 14th 2011Reviewed: December 17th 2011Published: March 28th 2012

DOI: 10.5772/38143

Downloaded: 9156

© 2012 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution 3.0 License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite and reference

Link to this chapter Copy to clipboard

Cite this chapter Copy to clipboard

Akira Takahara (March 28th 2012). Dual L/N-Type Ca2+ Channel Blocker: Cilnidipine as a New Type of Antihypertensive Drug, Antihypertensive Drugs Hossein Babaei, IntechOpen, DOI: 10.5772/38143. Available from:

Embed this chapter on your site Copy to clipboard

<iframe src="" />

Embed this code snippet in the HTML of your website to show this chapter

chapter statistics

9156total chapter downloads

More statistics for editors and authors

Login to your personal dashboard for more detailed statistics on your publications.

Access personal reporting

Related Content

This Book

Next chapter

Hypertension and Chronic Kidney Disease: Cause and Consequence – Therapeutic Considerations

By Elsa Morgado and Pedro Leão Neves

Related Book

First chapter

Oral Absorption, Intestinal Metabolism and Human Oral Bioavailability

By Ayman El-Kattan and Manthena Varma

We are IntechOpen, the world's leading publisher of Open Access books. Built by scientists, for scientists. Our readership spans scientists, professors, researchers, librarians, and students, as well as business professionals. We share our knowledge and peer-reveiwed research papers with libraries, scientific and engineering societies, and also work with corporate R&D departments and government entities.

+3,550 Open Access Books

+57,400 Citations in Web of Science

+108,500 IntechOpen Authors and Academic Editors

+560,000 Unique visitors per month

More about us